F-D-C Reports, Inc. Launches PharmAsiaNews.com
New online service covering RX drugs, biologics and devices
Rockville, Md. - January 14, 2008 - F-D-C Reports, Inc. announces the launch of PharmAsiaNews.com: a new subscription-based online service covering Rx drugs, biologics and devices in China, India, Japan and other nations in the Pacific Rim.
“By leveraging the editorial excellence of “The Pink Sheet,” the leading information source for U.S. pharmaceutical industry information since 1939 into the Asian markets and combining it with new features enabled by Web 2.0 technology, we believe PharmAsiaNews.com will become an important information service to multinational pharmaceutical companies who are making increasingly larger bets in the region” said Gerry Stoia, V.P. of Elsevier Health Science Division’s Pharma Solutions unit and President of F-D-C Reports, Inc.
“Increasingly over the past several years, customers have requested reliable, independent and accurate ‘Pink Sheet like’ coverage of business and regulatory developments in the APAC region. F-D-C Reports, Inc. has answered the call for information on developments in China, India, Japan and other countries in the region via our PharmAsiaNews.com service,” Stoia added.
The result is a publication that provides readers with the broadest spectrum of news sources, including: original on-the-ground reporting from news bureaus across Asia; guest columns; exclusive interviews; news summaries; English translation summaries of Chinese- and Japanese-language news; and aggregated content from around the globe.
“What makes PharmAsiaNews.com unique is our commitment to original local market coverage and insights developed by local staff who are resident in the market. This is not a service that provides solely rewritten press releases and translated local language stories. By leveraging Elsevier’s global footprint, we’ve brought local talent aboard to provide our customers with the ‘boots on the ground’ coverage our customers have requested,” said Joe Hecker, Editor-in-Chief at Elsevier’s F-D-C Reports, Inc.
Subscribers to PharmAsiaNews.com get online access to around-the-clock coverage of the rapidly expanding Asia marketplace, including China, India, Japan and other nations in the Pacific Rim; twice-weekly email updates; full archive access; breaking news alerts; and other online resources.
# # #
About F-D-C Reports
F-D-C Reports, Inc. provides up-to-date information about the worldwide health care industry via its publications including The Pink Sheet®, The Gray Sheet®, The Rose Sheet®, The Tan Sheet®, and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand the developments affecting the U.S. regulation and marketing of healthcare products and services. F-D-C Reports, Inc. has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the U.S. drug, biotechnology, medical device, nonprescription drug, nutritionals, and cosmetics industries. F-D-C Reports, Inc. is part of Elsevier.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
F-D-C Reports, Inc.
+1 240 221 4535